Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Co. June 20 announced that the Food and Drug Administration has approved updated labeling for Tradjenta (linagliptin) tablets and Jentadueto (linagliptin and metformin hydrochloride) tablets.
Tradjenta is used along with diet and exercise to improve glycemic control in adults with type 2 diabetes. Jentadueto can be used along with diet and exercise to help control blood sugar in adults with type 2 diabetes when treatment with both linagliptin and metformin is appropriate.
The companies said information about pancreatitis was included in the adverse reactions sections of the original labels for these products; ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.